



**Submission of CTIMPs**  
 R&D SOP 21 Version 1 – 24.03.2023

<b>Department</b>	Research, Development & Innovation
<b>Title of SOP</b>	Submissions for approvals to commence a Clinical Trial
<b>SOP reference no:</b>	R&D SOP 21
<b>Authors:</b>	G. Constable
<b>Current version number and date:</b>	Version 1, 24.03.2023
<b>Next review date:</b>	24.03.2026
<b>Target audience:</b>	Research, pharmacy and R&D staff
<b>Distribution:</b>	HUTH R&D internet Click on GCP SOPs for HUTH-sponsored CTIMPs <a href="https://www.hey.nhs.uk/research/researchers/gcp-sops-for-hey-sponsored-ctimps/">https://www.hey.nhs.uk/research/researchers/gcp-sops-for-hey-sponsored-ctimps/</a>
<b>When this document is viewed as a paper copy, the reader is responsible for checking that it is the most recent version.</b>	
<p>© Hull University Teaching Hospitals NHS Trust 2023 All Rights Reserved</p> <p>No part of this document may be reproduced, stored in a retrieval system or transmitted in any form or by any mean without the prior permission Hull University Teaching Hospitals NHS Trust R&amp;D department.</p>	

<b>Authorized by</b>	<b>Name</b>	<b>Sign</b>	<b>Date</b>
<b>RDI Director</b>	Professor Thozhukat Sathyapalan	 DocuSigned by: Prof Thozhukat Sathyapalan 645722D6386948C...	24/3/2023
<b>RDI Manager</b>	James Illingworth	 DocuSigned by: James Illingworth 3DDA0F96873F430...	24/3/2023

**Submission of CTIMPs**  
R&D SOP 21 Version 1 – 24.03.2023

This page details the version history and the main changes made for each new version.

<b>Version Log</b>		
<b>Version number and date</b>	<b>Author</b>	<b>Details of significant changes</b>
Version 1, (24.03.2023)	G Constable	First generation of SOP

**Submission of CTIMPs**  
R&D SOP 21 Version 1 – 24.03.2023

<b>Section no.</b>	<b>Contents</b>	<b>Page no.</b>
<b>1</b>	<b>Introduction, purpose and who should use this SOP</b>	<b>4</b>
<b>2</b>	<b>Scope</b>	<b>4</b>
<b>3</b>	<b>Overview of application process</b>	<b>5</b>
<b>4</b>	<b>User roles</b>	<b>6-7</b>
<b>5</b>	<b>Submitting an application</b>	<b>7</b>
<b>6</b>	<b>Regulatory Review</b>	<b>8</b>
<b>7</b>	<b>Request for Further Information</b>	<b>8</b>
<b>8</b>	<b>Implementation</b>	<b>8</b>

**Please note for definitions of acronyms refer to Appendix 1 of Management of SOPs. Refer to Appendix 2 of Management of SOPs for the standards to which clinical trials that investigate the safety and/or efficacy of a medicinal product are conducted.**

**All the HUTH R&D GCP SOPs are available at:**

<https://www.hey.nhs.uk/research/researchers/gcp-sops-for-hey-sponsored-ctimps/>

## 1 Introduction, purpose and who should use this SOP

- 1.1 This SOP describes the process of submitting a study to regulatory bodies for trials sponsored by Hull University Teaching Hospitals NHS Trust.
- 1.2 This SOP should be applied when a study has completed the trial set-up (highlighted in *R&D GCP SOP 04*)
- 1.3 It is a legal requirement to submit all studies to the relevant regulatory bodies in the UK.
- 1.4 All supporting documentation must be ready and files clearly named with a version number (to the whole number) and date in line with *R&D GCP SOP 01 Version Control*.
- 1.5 It is strongly encouraged for investigators to read the general guidance provided on the [HRA website](#) covering the combined review process.
- 1.6 The approvals required (*where applicable*) before a clinical trial can commence are:
  - Medicines and Healthcare products Regulatory Agency (MHRA) clinical trial authorization
  - Research Ethics Committee (REC) favourable opinion
  - Health Research Authority (HRA) approval (HCRW for Wales)
  - *Confidentiality Advisory Group (CAG)*
  - *Administration of Radioactive Substances Advisory Committee (ARSAC)*
  - MHRA Medical Devices
  - *His Majesty's Prison and Probation Service (HMPPS)*
  - R&D approval (confirmation of Capacity and Capability)
  - HUTH R&D QA as sponsor representative will send a 'green light' email to the CI/PI and research team to confirm that the trial can start.

Guidance for submission of the above can be found at

<https://www.myresearchproject.org.uk/help/hlphraapproval.aspx>

- 1.7 This SOP should be used by any investigators and trial teams requesting sponsorship by HUTH.

## 2 Scope

- 2.2 The SOP is applicable to all HUTH sponsored research studies and clinical trials. Where HUTH is co-sponsor on a clinical trials with another institution this SOP should be followed; any discrepancies between HUTH and the other co-sponsors SOP should be highlighted in the co-sponsor agreement.
- 2.3 As of 1<sup>st</sup> January 2022 combined review is the way all applications for new Clinical Trials of Investigational Medicinal Products (CTIMPs) and combined IMP/device trials must be made. For all other types of research an application should be prepared and submitted using '[standard IRAS](#)'.
- 2.4 Historically applications for clinical trials were sent separately to the MHRA for regulatory review, and to a Research Ethics Committee (REC) for ethics review. The combination of these applications into one portal will streamline the process as reviews are done in


**Submission of CTIMPs**  
R&D SOP 21 Version 1 – 24.03.2023

parallel. The application also goes for study wide review, such as HRA (and HCRW in Wales), if the study is to take place in the NHS or Northern Ireland HSC.

### 3 Overview of the application process


3.1 The following is taken from the [HRA guide for IRAS applications for combined review](#).

#### Overview of the application process



## 4 User Roles

- 4.1 A change to the IRAS application (that now goes through combined review) is that every project must have a Chief Investigator and a Project Deputy assigned, so there is always two people with access to the study.
- 4.1.1 The Chief investigator must accept their role in IRAS before the project is submitted. The Project Deputy is a new role in IRAS and they will support the CI and often manage the project in IRAS.
- 4.1.2 The Project Deputy has full access to the project and can completed all project related tasks in IRAS.
- 4.1.3 Once a project has been set up, the CI or Project Deputy can add as many 'collaborators' as they would like to work on that project. Collaborators can be added and removed as required throughout the project lifetime.
- 4.1.4 All collaborators can have edit access meaning they are able to change, add or delete information held in the system. Collaborators will have the same user rights as a Project Deputy and can work on the project after Initial Submission, including booking the REC, responding to the RFI, creating amendments or reports and providing the end of trial notification.
- 4.1.5 When the project has been authorised the collaborators will automatically be removed by IRAS. The CI or Project Deputy can re add the collaborators if/when required in order to build a research team that works for the project.
- 4.1.6 Collaborators can be from other departments, representatives from HUTH as a sponsor organisation can be added.
- 4.1.7 It is a requirement to add members of HUTH R&D QA team to assist in version controlling documents and finalising the submission.
- 4.1.8 Changes made by those with edit access will be stored once saved, so it is crucial that correct people have access to the project.
- 4.1.9 The person that sends the project to the Sponsor will receive the tasks in the system to book the REC and then to respond to any requests for further information (if needed). This is shown in a diagram below. This could be a collaborator so it is important to make sure this has been agreed within the trial team who will submit the study and respond to these follow-ups.




4.1.9 **NB Email correspondence about the project is ONLY sent to the contact listed in question C1, so do make sure the right person's contract details are listed. It is a requirement that the contact details of staff members of HUTH R&D QA are added to this question to ensure the team is kept up-to-date with developments of the study.**

## 5 Submitting an application

- 5.1 When all study documents have been finalised the study is ready for submission.
- 5.2 To assist in accurate submissions to the regulatory bodies, there are a plethora of guides available to help investigators; it is strongly encouraged to use the [HRA's step-by-step guide](#) for using IRAS for combined review.
- 5.3 Ensure all supporting documents are finalised, free-from errors or comments and version controlled as mentioned in 1.4.
- 5.4 If this is an investigators first time submitting through IRAS, the HRA will need to be contacted via [cwow@hra.nhs.uk](mailto:cwow@hra.nhs.uk) to set-up a user account. Guidance on the setting up of an IRAS account can be [found here](#).
- 5.5 When you have an IRAS account and the study is ready for submission sign into your IRAS account [here](#).
- 5.6 The process of making an initial submission can be found [here](#).
- 5.7 For HUTH sponsored CTIMPs it is required that R&D QA team members are added to the study as a 'collaborator'. This can be done via the Project Dashboard, under 'key associates'. This will enable our QA department to be notified on responses from submission.

## 6 Regulatory Review

6.1 Once submitted the application will be sent to all relevant parties for review. The target timelines are shown on the following flowchart, taken from the [HRA's website](#).



- 6.2 As shown in the flowchart **3.1** the REC review requires an in-person review to clarify points on the study for better understanding. Since the COVID-19 pandemic it has become favourable to perform REC reviews via online video platforms.
- 6.3 Once the MHRA and REC have reviewed the study they will issue an initial outcome and a Request for Further Information (RFI) may be issued.
- 6.4 The investigator team will respond to the RFI with any amended documentation or additional documents if requested. **All documentation should be reviewed by HUTH R&D QA prior to submission.** The release of an RFI to Combined Review is performed by the R&D manager as a sponsor representative.

## 7 Requests for Further Information

- 7.1 RFIs will be sent, as a task, to the user who initially submitted the application.
- 7.2 If more time is required to respond to an RFI, an extension can be formally requested by contacting [clintrialhelpline@mhra.gov.uk](mailto:clintrialhelpline@mhra.gov.uk), with a reference to how long over the 14 days is being requested.
- 7.3 To respond to an RFI log in to IRAS and follow My Tasks > My Personal Tasks > and select the project. Review and replies can then be made in the on-screen text box or submitted through an uploaded document if the replies are exceptionally long.
- 7.4 Once the RFI has been completed satisfactorily it can be submitted to 'request review'. The RFI will then go to the Sponsor or Sponsor Delegate's account under 'My tasks' > 'My organisational tasks' for a review and to make the final submission.

## 8 Implementation

- 8.1 Implementation of this SOP will conform to the process outlined in RDI SOP 01 Management of SOPs